CRVS241220C18000
- 0.20
- -0.10-33.33%
Corvus Pharmaceuticals Newsroom
A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $13 to $24
Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Corvus Pharma Analyst Ratings
Corvus Stock Climbs 7% Following Mizuho Upgrade
Mizuho Securities Upgrades Corvus Pharmaceuticals(CRVS.US) to Buy Rating, Announces Target Price $12
Corvus Pharma Analyst Ratings
Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $21
Ladenburg Thalmann Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $21
Analysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)
Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns
Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Adaptimmune Therapeutics (ADAP) and Corvus Pharmaceuticals (CRVS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Editas Medicine (EDIT), Corvus Pharmaceuticals (CRVS) and AC Immune SA (ACIU)
Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
Cantor Fitzgerald Reiterates Overweight on Corvus Pharma, Maintains $4 Price Target